You are here
Session on G-CSF: prophylaxis of febrile neutropenia
By Matti Aapro, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris
Febrile neutropenia is associated with considerable morbidity and mortality as well as increased costs. The use of G-CSF for the prevention of febrile neutropenia is a validated approach and G-CSF may also reduce the risk of asthenia, mucositis and diarrhea. Matti Aapro presents the guidelines of the French speaking association for supportive care in cancer (AFSOS) according to which G-CSF prophylaxis is indicated if a patients’ risk of febrile neutropenia is 20% or higher while patients with a risk of 10–20% should be evaluated with regard to their individual risk factors. Prevention is of major importance as it has been shown that comorbid conditions and infectious complications were significantly associated with increased mortality, but adherence to clinical guidelines is poor and patients are generally undertreated with G-CSF. Matti Aapro also reviews the different types of G-CSF and compares long-acting and short-acting G-CSF.
Matti Aapro, Clinique de Genolier, Switzerland